FAP and sarcoma: Four patients were positive for FAP expression [two receiving simlukafusp alfa 10 mg alone (with gastric or SI cancer) and one each receiving simlukafusp alfa 15/20 mg alone (with thymic cancer) and simlukafusp alfa 10 mg + atezolizumab (with sarcoma)], and one with renal pelvic cancer had high PDL1 expression (receiving simlukafusp alfa 10 mg + atezolizumab).